Mizuho Downplays Merck (MRK) KEYTRUDA Competition in 1L NSCLC

Go back to Mizuho Downplays Merck (MRK) KEYTRUDA Competition in 1L NSCLC

Merck (MRK) Tops Q3 EPS by 27c, Revenues Beat; Narrows & Raises FY19 EPS/Revenue Above Consensus

October 29, 2019 6:47 AM EDT

Merck (NYSE: MRK) reported Q3 EPS of $1.51, $0.27 better than the analyst estimate of $1.24. Revenue for the quarter came in at $12.4 billion versus the consensus estimate of $11.63 billion.

Third-Quarter 2019 Worldwide Sales Were $12.4 Billion, an Increase of 15%; Sales Increased 16% Excluding Impact from Foreign Exchange; Growth Driven by Oncology and Human Health VaccinesKEYTRUDA Sales Grew 62% to $3.1 Billion;... More

Merck (MRK) Trades Lower Following AstraZeneca (AZN) Imfinzi Results, Down 0.70%

October 28, 2019 11:39 AM EDT

Merck (NYSE: MRK) Trades Lower Following AstraZeneca (NYSE: AZN) Imfinzi Results, Down 0.70%

... More